Comparative effects of glucose and xylose on blood pressure, gastric emptying and incretin hormones in healthy older subjects

Lora Vanis¹,², Trygve Hausken³,⁴, Diana Gentilcore¹,², Rachael S. Rigda¹,², Christopher K. Rayner¹,², Christine Feinle-Bisset¹,², Michael Horowitz¹,² and Karen L. Jones¹,²*

¹Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia
²NHMRC Centre of Clinical Research Excellence in Nutritional Physiology, Interventions and Outcomes, University of Adelaide, Adelaide, SA 5000, Australia
³Institute of Medicine, University of Bergen, Bergen, Norway
⁴National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway

(Received 5 July 2010 – Revised 29 November 2010 – Accepted 30 November 2010 – First published online 4 February 2011)

Abstract

Postprandial hypotension is an important disorder for which current management is suboptimal. In healthy older subjects, oral and small-intestinal glucose administration decreases blood pressure (BP), and the magnitude of the reduction is dependent on the rate of glucose entry into the small intestine and, possibly, the release of glucagon-like peptide-1 (GLP-1). There is little information about the effects of other carbohydrates, particularly those poorly absorbed, on BP. The aim of the present study was to compare the effects of drinks containing xylose, glucose or water alone on BP, gastric emptying (GE), incretin hormone secretion, glycaemia and insulinaemia in healthy older subjects. A total of eight healthy older subjects (aged 65–75 years) had simultaneous measurements of BP (DINAMAP), GE (three-dimensional ultrasound), blood glucose, serum insulin, GLP-1 and glucose-dependent insulinotropic peptide (GIP), on three separate occasions, in a double-blind, randomised order. On each day, subjects consumed a 300 ml drink of water, glucose (50 g) or D-xylose (50 g). Glucose (P=0.02), but not xylose (P=0.63), was associated with a fall in BP. There was no difference in the GE of glucose and xylose (P=0.47); both emptied slower than water (P<0.001). Xylose had minimal effects on blood glucose, serum insulin or serum GIP, but was more potent than glucose in stimulating GLP-1 (P=0.002). In conclusion, in healthy older subjects, xylose empties from the stomach at the same rate as glucose, but has no effect on BP, possibly because it is a potent stimulus for GLP-1 release. Xylose may be considered as an alternative sweetener to glucose in the management of postprandial hypotension.

Key words: Ageing; Postprandial hypotension; Ultrasound; Monosaccharides; Glucagon-like peptide-1; Glucose-dependent insulinotropic peptide; Insulin

Postprandial hypotension (PPH), defined as a fall in systolic blood pressure (BP) ≥20 mmHg within 2 h of a meal¹, leads to syncope and falls, and is recognised as a frequent and clinically important problem, particularly in the elderly and patients with autonomic dysfunction, the latter often secondary to diabetes mellitus¹,². PPH is distinct from, and occurs more frequently than, orthostatic hypotension³. The mechanisms responsible for PPH are poorly defined; however, several factors including meal composition, gastric distension, small-intestinal nutrient delivery, splanchic blood flow and neural and hormonal mechanisms appear important¹,³–⁷. An understanding of these mechanisms is pivotal for the effective management of PPH, which is currently suboptimal.

The onset of the fall in BP is usually evident soon after a meal, with a maximum response at 30–60 min¹, suggesting a relationship to the delivery of nutrients to the small intestine, which has proven to be the case. When glucose is administered intraduodenally to healthy older subjects at rates of 4·2 kJ/min (1 kcal/min) or 12·6 kJ/min (3 kcal/min)⁷,⁸, i.e., within the normal physiological range of gastric emptying (GE)⁹, the fall in BP is much greater in response to 12·6 kJ/min (3 kcal/min) when compared with 4·2 kJ/min (1 kcal/min). In contrast, gastric distension, probably even at low volumes, attenuates the fall in BP⁶,⁷. Ingestion of carbohydrate, particularly glucose, was believed to have the greatest suppressive effect on BP¹⁰ when compared with fat and

Abbreviations: AUC, area under the curve; BP, blood pressure; bpm, beats per min; G, glucose; GE, gastric emptying; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; POM, three-dimensional positioning and orientation measuring; PPH, postprandial hypotension; X, D-xylose; W, water.

* Corresponding author: Professor K. L. Jones, fax +61 8 8223 3870, email karen.jones@adelaide.edu.au
protein\textsuperscript{(11)}, but recent studies by our group have shown that oral\textsuperscript{(12)} and intraduodenal\textsuperscript{(12,13)} infusion of fat, protein and glucose\textsuperscript{(13)} induces comparable falls in BP in healthy older subjects, although the hypotensive response to glucose occurs earlier than with fat or protein\textsuperscript{(12,13)}. There is little information about the effect of different carbohydrates on post-prandial BP, particularly those that are absorbed more slowly than glucose. Xylose is a poorly absorbed pentose, commonly found in plant cell walls, which is used as a food additive to produce a ‘savoury’ flavour\textsuperscript{(14)}. Information relating to the effects of xylose on BP is inconsistent. It has been reported that there is no fall in BP after oral xylose in amounts of 42\textsuperscript{(15)} and 0.83 g/kg body weight\textsuperscript{(16)} in healthy older subjects who exhibited a fall in BP following oral glucose, whereas Mathias et al.\textsuperscript{(17,18)} suggested that there is a small fall in BP following oral xylose. A limitation of these studies\textsuperscript{(15–18)} was that GE of glucose and xylose was not measured, and differences in the rate of carbohydrate delivery into the small intestine may have, accordingly, influenced the observations. In monkeys, the GE of xylose apparently occurs in a similar fashion to that of glucose; i.e. in an overall linear pattern and more slowly with increasing concentration, presumably as a result of inhibitory feedback arising from the small intestine\textsuperscript{(19)}. In contrast, in humans, xylose (25 g) has been reported to markedly prolong GE when compared with the same amount of glucose\textsuperscript{(20)}.

The ‘incretin hormones’, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are responsible for the substantially greater insulin response to oral glucose compared with isoglycaemic intravenous glucose loads\textsuperscript{(21)}. GLP-1 is secreted by L-cells located predominately in the distal small intestine and colon, and suppresses glucagon secretion, as well as stimulating glucose-dependent insulin secretion, while GIP is released from the K-cells, which are located predominantly in the proximal small intestine\textsuperscript{(21,22)}. Recent observations have suggested that GLP-1 may have a protective role in PPH. In humans\textsuperscript{(23)} and animals\textsuperscript{(24)}, exogenous administration of GLP-1 may increase BP. We have reported that the α-glucosidase inhibitor, acarbose, which is used frequently in the management of type 2 diabetes, attenuates the fall in BP induced by oral sucrose in healthy older subjects, slows GE and markedly stimulates the secretion of GLP-1\textsuperscript{(25)}. The latter effect presumably reflects the presence of carbohydrate in the small intestine. In dogs, there was no increase in the release of GLP-1 following an infusion of xylose into an ileal loop\textsuperscript{(26)}. The effects of carbohydrate on GLP-1 secretion may, however, be species-dependent\textsuperscript{(27)}, and there is no information about the effects of xylose on GIP and GLP-1 in humans.

The aims of the present study were to determine the effects of oral xylose on BP, GE and incretin hormone secretion, when compared with oral glucose and water, in healthy older subjects.

Materials and methods

Subjects

A total of eight healthy older subjects (six males and two females), with a median age of 70.5 (range 65–75) years and BMI of 23.5 (range 20.4–27.1) kg/m\textsuperscript{2}, were recruited by advertisement. All were non-smokers, and none had a history of gastrointestinal disease or surgery, diabetes, significant respiratory, renal, hepatic or cardiac disease, intake of >20 g alcohol/d or was taking medication known to influence BP or gastrointestinal function.

Protocol

The protocol was approved by the Human Research Ethics Committee of the Royal Adelaide Hospital, and each subject provided written informed consent. All experiments were carried out in accordance with the Declaration of Helsinki.

Each subject was studied on three occasions in a randomised, double-blind order; each study day was separated by a minimum of 3 d. On each day, the subject attended the laboratory at 08.00 hours following an overnight fast (10 h for solids and 8 h for liquids). An intravenous cannula was placed in a left antecubital vein for blood sampling, and an automated BP cuff positioned around the right arm for the measurement of BP and heart rate. Each subject was then allowed to rest, seated in a chair, for about 30 min. At t = −2 min, the subject consumed a 300 ml drink comprising either (1) water (50 ml low-energy lemon cordial (Bickford’s, Adelaide, SA, Australia) + 250 ml water) – ‘W’, (2) 50 g glucose monohydrate (dissolved in 50 ml low-energy lemon cordial + 155 ml water + 80 ml hypertonic saline (3%)) – ‘G’ or (3) 50 g D-xylose (dissolved in 50 ml low-energy lemon cordial + 235 ml water) – ‘X’, within 2 min. Both carbohydrate drinks were isoenergetic (approximately 782.4 kJ (187 kcal)) and iso-osmolar (approximately 1350 mOsmol). GE, BP (systolic and diastolic) and heart rate were then measured for 120 min. On one day, cardiovascular autonomic nerve function was evaluated immediately after the completion of the study\textsuperscript{(20,29)}.

Measurements

Blood pressure and heart rate. BP (systolic and diastolic) and heart rate were measured using an automated oscillometric BP monitor (DINAMAP ProCare 100; GE Medical Systems, Milwaukee, WI, USA) before the consumption of the drink and then every 3 min between t = 0 and 120 min\textsuperscript{(7)}. ‘Baseline’ BP and heart rate, i.e. ‘t = 0 min’, were calculated as the mean of measurements taken at t = −9, −6 and −3 min. PPH was defined as a fall in systolic BP of ≥20 mmHg that was sustained for at least 30 min.\textsuperscript{(11)}

Gastric emptying. GE was assessed using three-dimensional ultrasonography, using a Logiq\textsuperscript{™} 9 ultrasonography system (GE Healthcare Technologies, Sydney, Australia) with TruScan Architecture (i.e. built-in magnetically sensored three-dimensional)\textsuperscript{(30)}. For three-dimensional positioning and orientation measurement (POM), a transmitter was placed close to the subject, and a snap-on sensor attached to a 3.5C...
blood pressure (26·5–4·4 MHz) convex transducer(28,29). As the transmitter produces a spatially varying magnetic field, and ferrous and conductive metals distort the magnetic field, all metal objects were removed from the subject and from the area directly between the POM transmitter and sensor(32). The POM transmitter was placed behind (approximately 10 cm) the subject(33), at the level of the stomach, so that the subject was positioned between the ultrasound scanner and the transmitter. For three-dimensional data acquisition, the subject was scanned at $t = -2$ and 0 min (i.e., immediately following drink consumption) and then at 15 min intervals between 0 and 120 min. A region of interest was drawn around the total stomach, and the volume of the drink in the total stomach was derived and expressed as a percentage of the original volume at $t = 0$ min (i.e. 100%)(30). GE curves (expressed as % retention over time) were derived for the total stomach at $t = 0$, 15, 30, 45, 60, 75, 90, 105 and 120 min. The 50% GE time was also determined.

**Blood glucose, serum insulin, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide concentrations.**

Venous blood samples were obtained before consumption of the drink (i.e. $t = -2$ min) and at 15 min intervals between $t = 0$ and 120 min. Blood glucose concentrations (mmol/l) were determined immediately using a portable blood glucose meter (Medisense Precision Q·I·D™ System; Abbott Laboratories, Medisense Products, Inc., Bedford, MA, USA).

Serum was separated by centrifugation at 3200 rpm for 15 min at 4°C within 30 min of collection and stored at $-70^\circ$C until analysed. Serum insulin (mU/l) was measured by ELISA immunoassay (Diagnostics Systems Laboratories, Inc., Webster, TX, USA). Sensitivity of the assay was 0·26 mU/l, and CV was 2·6% within assays and 6·2% between assays(34).

Serum GLP-1 (pmol/l) was measured by RIA (GLPIT-36HK; Linco Research, St Charles, MO, USA). Minimum detection limit was 3 pmol/l, intra-assay CV was 6·7% and inter-assay CV was 7·8%.

Serum GIP (pmol/l) was measured by RIA with some modifications to the original method(35). The standard curve was prepared in buffer rather than in extracted charcoal-stripped serum, and the radio-iodinated label was supplied by Perkin Elmer (Boston, MA, USA). Minimum detection limit of the assay was 2 pmol/l, and both intra- and inter-assay CV were 11·2 and 11·6%, respectively.

**Autonomic function.** Autonomic nerve function was assessed using standardised cardiovascular reflex tests(28,29). In brief, parasympathetic function was evaluated by the variation (R–R interval) of the heart rate during deep breathing and the response to standing (%) 30:15’ ratio). Sympathetic function was assessed by the fall in systolic BP in response to standing. Each of the test results was scored according to age-adjusted predefined criteria as 0 normal, 1 borderline and 2 abnormal for a total maximum score of 6. A score $>$ 3 was considered to indicate autonomic dysfunction(28,29).

**Statistical analysis.** Systolic and diastolic BP and heart rate were expressed as changes from baseline. GE, blood glucose, serum insulin, and GLP-1 and GIP concentrations were analysed as absolute values. One-way ANOVA was used to analyse the effects of ‘time’ on GE, systolic and diastolic BP, heart rate, blood glucose, serum insulin, and GLP-1 and GIP concentrations. The maximum fall in systolic and diastolic BP and maximum rise in heart rate were defined as the greatest change from baseline in each subject at any given time point for each treatment. For blood glucose, serum insulin, and GLP-1 and GIP concentrations, the peak absolute value was analysed in each subject at any given time point for each treatment. Areas under the curve (AUC), between $t = 0$ and 120 min, were calculated using the trapezoidal rule and analysed by one-way ANOVA to evaluate the ‘treatment’ effect for GE, systolic and diastolic BP and heart rate and between $t = -2$ and 120 min for blood glucose, serum insulin, and GLP-1 and GIP concentrations. All analyses were performed using SPSS version 16.0.2 (SPSS, Inc, Chicago, IL, USA). Data are shown as changes from baseline and means with their standard errors, unless otherwise stated. The number of subjects studied was based on power calculations derived from our previous work; the sample size of eight subjects was calculated to have 80% power at the $P=0·05$ significance level to detect a difference in maximum fall in systolic BP between glucose and xylitol of 7·3 mmHg(36). A $P$ value $<0·05$ was considered significant in all analyses.

**Results**

The studies were well tolerated, and there were no adverse events. No subject had definite autonomic neuropathy (mean score 0·9, range 0–2), or had PPH.

**Blood pressure and heart rate**

There was no difference in baseline $(t = 0)$ BP or heart rate between the $3 \times 3 : 1$; systolic BP $(‘W’ 118·4 \text{(SEM 6·0)} \text{mmHg} v. ‘G’ 120·4 \text{(SEM 7·0)} \text{mmHg} v. ‘X’ 118·9 \text{(SEM 5·6)} \text{mmHg}; P=0·44)$; diastolic BP $(‘W’ 70·3 \text{(SEM 3·0)} \text{mmHg} v. ‘G’ 71·1 \text{(SEM 2·7)} \text{mmHg} v. ‘X’ 70·3 \text{(SEM 3·0)} \text{mmHg}; P=0·40)$; heart rate $(‘W’ 58·9 \text{(SEM 2·2)} \text{beats per min (bpm)} v. ‘G’ 58·8 \text{(SEM 3·0)} \text{bpm} v. ‘X’ 59·1 \text{(SEM 2·6)} \text{bpm}; P=0·79)$. During ‘G’, the maximum fall in BP was 15·1 (SEM 2·8) mmHg occurring at 64 (SEM 5·7) mmHg; $P=0·23$), ‘G’ (119·4 (SEM 5·7) mmHg; $P=0·69$) or ‘X’ (117·6·4 (SEM 4·6) mmHg; $P=0·43$).

**Systolic blood pressure**

Between $t = 0$ and 120 min, there was a fall in systolic BP during ‘G’ $(P=0·02)$ and no change during ‘W’ $(P=0·71)$ or ‘X’ $(P=0·63)$ (Fig. 1(a)). There was a treatment effect $(P<0·001)$ for the AUC of the change in systolic BP between $t = 0$ and 120 min, so that systolic BP was less during ‘G’ when compared with ‘W’ and ‘X’ $(P=0·003$ for both), without any difference between ‘W’ and ‘X’ $(P=0·19)$. During ‘G’, the maximum fall in BP was 15·1 (SEM 2·8) mmHg occurring at 64 (SEM 9) min. At $t = 120$ min, systolic BP was not different from baseline after ‘W’ (120·6 (SEM 0·0) mmHg; $P=0·23$), ‘G’ (119·4 (SEM 5·7) mmHg; $P=0·69$) or ‘X’ (117·6·4 (SEM 4·6) mmHg; $P=0·43$).
**Diastolic blood pressure**

Between \( t = 0 \) and 120 min, there was a fall in diastolic BP during ‘G’ \((P=0·003)\), and no change during ‘W’ \((P=0·88)\) or ‘X’ \((P=0·26)\) (Fig. 1(b)). There was a treatment effect \((P<0·001)\) for the AUC of the change in diastolic BP between \( t = 0 \) and 120 min, so that diastolic BP was less during ‘G’ when compared with ‘W’ \((P=0·005)\), without any significant difference between ‘W’ and ‘X’ \((P=0·92)\). During ‘G’, the maximum fall in BP was 12·9 \((\text{SEM} 1·6)\) mmHg occurring at 56 \((\text{SEM} 11)\) min. At \( t = 120 \text{ min}\), diastolic BP was not different from baseline after ‘W’ \((69·6 \text{ (SEM} 3·3)\) mmHg; \(P=0·58)\), ‘G’ \((69·6 \text{ (SEM} 3·3)\) mmHg; \(P=0·41)\) or ‘X’ \((71·9 \text{ (SEM} 2·6)\) mmHg; \(P=0·27)\).

**Heart rate**

Between \( t = 0 \) and 120 min, there was no significant change in heart rate during ‘W’ \((P=0·22)\), ‘G’ \((P=0·28)\) or ‘X’ \((P=0·19)\) (Fig. 1(c)). At \( t = 120 \text{ min}, \) heart rate was not significantly different from baseline after ‘W’ \((57·5 \text{ (SEM} 2·5)\) bpm; \(P=0·77)\), ‘G’ \((59·5 \text{ (SEM} 2·8)\) bpm; \(P=0·63)\) or ‘X’ \((64·8 \text{ (SEM} 5·1)\) bpm; \(P=0·15)\).

**Gastric emptying**

There was a significant treatment effect \((P<0·001)\) for the AUC for GE between \( t = 0 \) and 120 min (Fig. 2). ‘W’ emptied in an overall exponential, and more rapid, fashion when compared with ‘G’ and ‘X’, which emptied linearly and more slowly \((P<0·001 \text{ for both})\), with no significant difference between ‘G’ and ‘X’ \((P=0·47)\). The 50 % GE time of ‘W’ \((t = 19 \text{ (SEM}\) 3 min)\) was less than ‘G’ \((t = 75 \text{ (SEM} 7)\) min) and ‘X’ \((t = 75 \text{ (SEM} 8)\) min) \((P<0·001)\).

**Blood glucose**

There was no difference in baseline \((t = -2 \text{ min})\) blood glucose between the 3 d (‘W’ \(v. \) ‘G’ \(v. \) ‘X’): 6·2 \((\text{SEM} 0·2)\) mmol/l \(v. \) 6·2 \((\text{SEM} 0·2)\) mmol/l \(v. \) 6·1 \((\text{SEM} 0·2)\) mmol/l; \(P=0·89).\) Between \( t = -2 \) and 120 min, there was a rise in blood glucose during ‘G’ \((P<0·001)\), and a slight rise following ‘X’ \((P=0·03)\), but no change during ‘W’ \((P=0·50)\) (Fig. 3(a)). There was a significant treatment effect \((P<0·001)\) for the AUC of the blood glucose concentration between \( t = -2 \) and 120 min, so that the magnitude of the rise in blood glucose was much greater during ‘G’ compared with both ‘W’ \((P=0·001)\) and ‘X’ \((P=0·001)\). During ‘G’, peak blood glucose was 10·2 \((\text{SEM} 0·6)\) mmol/l at 53 \((\text{SEM} 8)\) min. At \( t = 120 \text{ min}, \) blood glucose concentrations were not different from baseline after ‘W’ \((6·1 \text{ (SEM} 0·1)\) mmol/l; \(P=0·58)\), ‘G’ \((6·8 \text{ (SEM} 0·2)\) mmol/l; \(P=0·09)\), ‘X’ \((6·3 \text{ (SEM} 0·2)\) mmol/l; \(P=0·30)\).
0.5 mmol/l; \( P = 0.33 \)), but were slightly higher after ‘X’ (6.5 (SEM 0.2) mmol/l; \( P = 0.03 \)).

**Serum insulin**

There was no difference in baseline \( (t = -2 \text{ min}) \) serum insulin between the 3 d (*W* v. ‘G’ v. ‘X’): 8.7 (SEM 1.3) v. 8.5 (SEM 1.1) v. 8.4 (SEM 1.3) mU/l; \( P = 0.88 \). Between \( t = -2 \) and 120 min, there was a rise in serum insulin during ‘G’ \( (P < 0.001) \), a trend for a fall during ‘W’ \( (P = 0.06) \) and no change during ‘X’ \( (P = 0.18) \) (Fig. 3(b)). There was a significant treatment effect \( (P < 0.001) \) for the AUC of serum insulin between \( t = -2 \) and 120 min, so that the magnitude of the rise in serum insulin was much greater during ‘G’ compared with ‘W’ and ‘X’ \( (P < 0.001) \) for both), without any significant difference between ‘W’ compared with ‘X’ \( (P = 0.15) \). At \( t = 120 \text{ min} \), serum insulin concentrations were not different from baseline after ‘W’ (15.7 (SEM 1.2) mU/l; \( P = 0.03 \)), slightly lower following ‘W’ (7.3 (SEM 1.0) mU/l; \( P = 0.03 \)) and substantially higher after ‘G’ (42.8 (SEM 10.1) mU/l; \( P = 0.009 \)).

**Serum glucagon-like peptide-1**

There was no significant difference in baseline \( (t = -2 \text{ min}) \) serum GLP-1 between the 3 d (*W* v. ‘G’ v. ‘X’): 16.6 (SEM 2.3) v. 13.8 (SEM 1.4) v. 18.9 (SEM 3.3) pmol/l; \( P = 0.08 \). Between \( t = -2 \) and 120 min, there was a rise in serum GLP-1 during ‘G’ \( (P = 0.01) \) and ‘X’ \( (P < 0.001) \), but no change during ‘W’ \( (P = 0.39) \) (Fig. 3(c)). There was a significant treatment effect \( (P \leq 0.001) \) for the AUC of serum GLP-1 concentration between \( t = -2 \) and 120 min, so that the magnitude of the rise in serum GLP-1 was much greater during ‘X’ compared with ‘W’ \( (P \leq 0.001) \) and ‘G’ \( (P = 0.002) \), with a trend for a difference between ‘G’ compared with ‘W’ \( (P = 0.07) \). During ‘G’, peak GLP-1 was 30.5 (SEM 4.6) pmol/l at 26 (SEM 5) min, and during ‘X’, peak GLP-1 was 42.0 (SEM 4.0) pmol/l at 48 (SEM 5) min \( (P < 0.05 \) for peak and \( P < 0.01 \) for time to peak). At \( t = 120 \text{ min} \), serum GLP-1 concentrations were not different from baseline after ‘W’ (15.7 (SEM 1.2) pmol/l; \( P = 0.15 \)) and ‘G’ (12.3 (SEM 1.0) pmol/l; \( P < 0.001 \), but higher following ‘X’ (27.2 (SEM 1.8) pmol/l; \( P = 0.002 \)).

**Serum glucose-dependent insulino tropic polypeptide**

There was no significant difference in baseline \( (t = -2 \text{ min}) \) serum GIP between the 3 d (*W* v. ‘G’ v. ‘X’): 17.3 (SEM 1.3) v. 18.4 (SEM 1.6) pmol/l v. 18.9 (SEM 1.6) pmol/l; \( P = 0.30 \). Between \( t = -2 \) and 120 min, there was a prompt rise in serum GIP during ‘G’ \( (P < 0.001) \), and a fall, albeit minor, during ‘W’ and ‘X’ \( (P < 0.001 \) for both) (Fig. 3(d)). There was a significant treatment effect \( (P \leq 0.001) \) of the AUC for serum GIP concentration between \( t = -2 \) and 120 min, so that the magnitude of the rise in serum GIP was much greater during ‘G’ compared with ‘W’ and ‘X’ \( (P \leq 0.001 \) for both), without any difference between ‘W’ compared with ‘X’ \( (P = 0.41) \). During ‘G’, peak GIP was 61.0 (SEM 8.0) pmol/l at 56 (SEM 11) min. At \( t = 120 \text{ min} \), serum GIP concentrations were not different from baseline after ‘W’ (15.7 (SEM 2.0) pmol/l; \( P = 0.15 \)), less following ‘X’ (16.2 (SEM 1.1) pmol/l; \( P = 0.02 \)) and greater after ‘G’ (48.9 (SEM 4.7) pmol/l; \( P < 0.001 \)).

Fig. 3. Change in (a) blood glucose, (b) serum insulin, (c) serum glucagon-like peptide-1 (GLP-1) and (d) serum glucose-dependent insulino tropic polypeptide (GIP) in response to oral water (*W*, ●), glucose (*G*, ○) and xylose (*X*, △). Values are means, with their standard errors represented by vertical bars (n 8). Mean values were significantly different for ‘G’ when compared with ‘W’ and ‘X’ for the blood glucose, serum insulin and serum GIP effects (***\( P \leq 0.001 \)). Mean values were significantly different for ‘X’ when compared with ‘W’ and ‘G’ for the serum GLP-1 treatment effect (**\( P \leq 0.01 \)).
Discussion

The present study indicates that oral xylose (50 g), unlike glucose, has no effect on BP in healthy older subjects despite emptying from the stomach at a comparable rate. Xylose is also more potent than glucose in stimulating GLP-1, but has no effect on GIP and has minimal effect on glycaemia and insulinemia, at least during euglycaemia.

The present study confirms that oral glucose induces a substantial fall (15·1 (SEM 2·8) mmHg) in systolic BP in healthy older subjects, studied under resting conditions. Previous studies relating to the effects of xylose on BP have been inconsistent(15–18), but GE was not measured in any of these studies, and may have potentially accounted for the observations, given that the rate of nutrient delivery into the small intestine affects the fall in BP both as a result of gastric distension(10,37) and as a result of the exposure of the small intestine to nutrients(7).

The present study establishes that glucose and xylose empty from the stomach at a comparable rate with an overall linear pattern that is substantially slower than water, which empties exponentially, consistent with a previous animal (primate) study(19). Hence, GE does not account for the different effects of glucose and xylose on BP. The regulation of the GE of nutrients arises predominantly as a result of inhibitory feedback from receptors in the small intestine, the magnitude of which is dependent on the length and, possibly, region(58) of the small intestine exposed, as influenced by the energy load. Accordingly, it appears that the magnitude of this inhibitory feedback is comparable for xylose and glucose, although the mechanism(s) which account for this feedback may differ(19).

In humans, a study in healthy adults males reported that xylose in a dose of 25 g in 50 ml water, given immediately after the consumption of a scrambled egg meal, markedly prolonged GE, when compared with the same amount of glucose(20). Differences in the rate of the GE of xylose between these studies, possibly influenced by the xylose dose, may account for the discrepant observations.

While it is clear that differences in GE do not account for the substantial, differential effects of xylose and glucose on BP, the two sugars had discrepant effects on glycaemia, insulinemia and the secretion of the incretin hormones, GIP and GLP-1, which, accordingly, warrant consideration. It is well documented, and confirmed in the present study, that xylose has minimal, if any, effect on plasma glucose or insulin(10–18).

However, both hyperglycaemia and hyperinsulinaemia are unlikely to play a major role in PPH, e.g. intravenous glucose has little, if any, effect on BP(19). The comparative effects of xylose and glucose on splanchnic blood flow remain to be determined, and it is possible that the relatively poorly absorbed xylose induces a lesser increase. This is the first evaluation of the effect of xylose on the release of GLP-1 and GIP – that xylose had no effect on GIP is predictable, given that the secretion of GIP occurs predominantly in the proximal small intestine and, in the case of carbohydrate, appears to be dependent on an affinity for the transporter, sodium-dependent glucose cotransporter-1(27). There is also no evidence that GIP affects BP. It has been reported that xylose has no effect on GLP-1 secretion in the dog(26), although xylose apparently stimulates the release of glucagon-like immunoreactivity in the canine intestine(40).

The present study establishes that xylose is a potent stimulant of GLP-1 in humans – the sustained stimulation is likely to reflect the delay in intestinal absorption when compared with glucose, so that the distal small intestine is exposed; the initial stimulation appeared similar to that induced by glucose. It is not surprising that the stimulation of GLP-1 by xylose was not associated with a substantial increase in serum insulin in the present study, as the insulinotropic property of GLP-1 is known to be glucose-dependent, i.e. GLP-1 has little, if any, effect on insulin during euglycaemia(21).

It is accordingly probable that xylose will stimulate insulin in type 2 patients during hyperglycaemia by increasing GLP-1. The stimulation of GLP-1 secretion by xylose may also be of relevance to the use of dipeptidyl peptidase-IV inhibitors and GLP-1 analogues in the management of type 2 diabetes(41). As discussed, this stimulation of GLP-1 may account for the absence of any fall in BP. We studied a small number of subjects precluding assessment of meaningful correlations. Further studies are required to address this issue, including the effects of different xylose loads. Given that GLP-1 plays a physiological role to slow GE(42), it is perhaps surprising that xylose did not empty from the stomach slower than glucose. However, it should also be recognised that glucose ingestion increased the blood glucose concentration substantially, whereas xylose did not, and elevations of blood glucose, even within a normal postprandial range, slow GE(43). It is also not known whether the presence of xylose in a glucose drink could attenuate the fall in BP. Furthermore, the effects of xylose in patients with PPH remain to be determined. In considering the potential dietary use of xylose, it should be recognised that while xylose is palatable, it is relatively expensive. In view of our observations, it would be of interest to evaluate the effects of the related pentose sugar, xylitol(44), which is considerably cheaper.

In summary, in healthy older subjects, oral xylose, unlike glucose in a dose of 50 g, has no effect on BP, despite emptying from the stomach at a comparable rate with glucose, and is a potent stimulant of GLP-1 secretion. These observations suggest that xylose may represent an alternative sweetener to glucose in the management of PPH.

Acknowledgements

The authors have no conflicts of interest or financial interests to declare. The present study was supported by the National Health and Medical Research Council (NHMRC) of Australia. Professor Jones’ and Professor Feinle-Bisset’s salaries are funded by the NHMRC of Australia, and Dr Gentilcore was supported by a Postdoctoral Fellowship from the National Heart Foundation of Australia (PR 07A 3309). The purchase of the Logiq 9 ultrasonography system was supported by an Equipment Grant from the NHMRC of Australia and funds from the University of Adelaide and GE Medical Systems Australia. The authors’ contributions are as follows: L. V. performed the acquisition of subjects, data collection, analysis...
and interpretation, and preparation of the manuscript; T. H. and D. G. contributed to the data collection and preparation of the manuscript; R. S. R. performed the data collection; C. K. R. and C. F.-B. contributed to the preparation of the manuscript; M. H. performed the data analysis and interpretation, and contributed to the preparation of the manuscript; K. L. J. contributed to the concept and design of the study, data analysis and interpretation, and preparation of the manuscript.

References